Gain Therapeutics Q2 net loss per share narrows as R&D expenses fall

Gain Therapeutics

11/08/2026 12:29

Overview
Biotechnology firm's Q2 net loss per share narrowed yr/yr to $0.11
R&D expenses fell due to lower costs for lead compound and personnel
FDA cleared IND for rexaceract, enabling Phase 2 clinical development

Outlook
Company expects to begin Phase 2 trial of rexaceract in Parkinson's disease in Q3 2026
Final results from Phase 1b clinical study of rexaceract expected in Q4 2026
GT-04686 initial target indication expected to be selected by year end

Result Drivers
R&D EXPENSES - Decrease in R&D expenses was mainly due to lower costs for lead program rexaceract and reduced research and development personnel expenses, partially offset by grant expiration and unfavorable currency translation
G&A EXPENSES - Increase in general and administrative expenses was due to higher professional fees, personnel costs, and unfavorable currency translation

Company press release: ID:nGNXjff7s

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Loss Per Share
 
$0.11
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Gain Therapeutics Inc is $8.00, about 352% above its August 10 closing price of $1.77

Reuters Recommended Reads
Aug 10 - CervoMed Q2 net loss lower than estimates as costs drop
Aug 10 - Biohaven Q2 net loss narrows on lower R&D spend
Aug 11 - Upstream Bio Q2 net loss narrows slightly on lower R&D costs

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)